Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AL
ALX Oncology Holdings Inc. Common Stock
ALXO
Mkt Cap
$147.0M
Volume
2.20M
Next Earnings
November 6th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AL
ALXO
AL
ALX Oncology Holdings Inc. Common Stock
ALXO
News
·
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Mkt Cap
$146.6M
Volume
2.20M
Next Earnings
November 6th
Chart
Financials
Earnings
News
About
Insider
Filings
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
ALX Oncology reported Q4 2025 financial results with improved net losses and announced strong clinical progress for its lead candidates evorpacept and ALX2004. The company validated CD47 as a predictive biomarker for evorpacept response in cancer trials, completed a $150 million equity offering extending cash runway through H1 2028, and appointed Barbara Klencke as permanent Chief Medical Officer. Multiple clinical milestones are anticipated over the next 12-18 months.
GlobeNewswire Inc. · Feb 27, 2026
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
ALX Oncology announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, with CEO Jason Lettmann and CMO Barbara Klencke delivering a corporate presentation on January 15, 2026. The clinical-stage biotech company is advancing evorpacept, a CD47-inhibitor being evaluated across multiple cancer indications, and ALX2004, an EGFR-targeted antibody-drug conjugate in Phase 1 trials.
GlobeNewswire Inc. · Jan 8, 2026
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
ALX Oncology reported impressive results from a Phase 2 trial combining evorpacept with rituximab and lenalidomide in treating indolent non-Hodgkin lymphoma, achieving a 92% complete response rate and 100% overall response rate.
GlobeNewswire Inc. · Dec 7, 2025
HER2-positive Gastric Cancer Clinical Trial Pipeline: Insights into a Growing Landscape with 20+ Companies Advancing Novel Treatments| DelveInsight
The HER2-positive gastric cancer market is experiencing sustained growth, with over 20 companies developing novel targeted therapies, driven by advances in precision medicine and expanded HER2 testing.
GlobeNewswire Inc. · Nov 27, 2025
ALX Oncology to Present at Upcoming Investor Conferences
ALX Oncology will participate in two healthcare conferences in November and December 2025, presenting their ongoing clinical-stage cancer therapies, including lead candidate evorpacept and new pipeline candidate ALX2004.
GlobeNewswire Inc. · Nov 18, 2025
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
Revolution Medicines appointed Alan Sandler, M.D. as chief development officer and added regional general managers in the U.S. and Europe to support potential approvals of RAS-targeted cancer therapies.
GlobeNewswire Inc. · Sep 29, 2025
Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight
The gastric cancer treatment market is expected to grow positively by 2034, driven by advances in targeted therapies and immunotherapies, with emerging drugs from multiple pharmaceutical companies showing promise in treating HER2-positive and advanced gastric cancers.
GlobeNewswire Inc. · Aug 11, 2025
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
ALX Oncology announced it will host a webcast event on May 20, 2025, to provide an update on its investigational antibody-drug conjugate ALX2004, which is designed to treat EGFR-expressing tumors.
GlobeNewswire Inc. · May 13, 2025
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
The global cancer market is projected to surpass $900 billion by 2034, driven by advancements in cancer treatments from biotech companies like Oncolytics Biotech, Exelixis, Cardiff Oncology, ALX Oncology, and Verastem.
Benzinga · Mar 8, 2025
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
ALX Oncology announced that the updated results from its Phase 2 ASPEN-06 clinical trial of evorpacept in combination with trastuzumab, CYRAMZA, and paclitaxel for the treatment of HER2-positive gastric/gastroesophageal junction cancer will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium.
GlobeNewswire Inc. · Dec 18, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AL
ALXO
ALX Oncology Holdings Inc. Common Stock
Buy
Sell
Market
Limit
Soon
ALXO
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ALXO yet.
Related Tickers
Earnings